In the News | Friends of Cancer Research

You are here

In the News

December 21, 2010
FDA Releases Guidance Based on Friends of Cancer Research and Brookings Institution Conference Each year Friends of Cancer Research (Friends) and the Engelberg Center for Health Care Reform at... Read more
December 20, 2010
By SHIRLEY HALEY Clinical trial strategies proposed in FDA's draft guidance for co-development of drugs designed for use in combination in most cases whittle the design down to standard of care... Read more
December 16, 2010
By Lisa Richwine and Ben Hirschler Roche's (ROG.VX) top drug Avastin should no longer be approved for breast cancer,  U.S. regulators said on Thursday, in an unusual move that could shave $1 billion... Read more
December 16, 2010
On December 14, 2010, Friends of Cancer Research (Friends) Chair and Founder, Dr. Ellen Sigal presented before the President's Cancer Panel. Her presentation was given in conjunction with the release... Read more
December 15, 2010
By AMY DOCKSER MARCUS When it comes to developing drugs, the FDA wants companies to do it together. Or at least to consider the possibility. The FDA today issued draft guidelines designed to... Read more
December 8, 2010
By WILL DUNHAM Elizabeth Edwards, a best-selling author and the driving force behind her husband John Edwards's political career  before it was destroyed by his infidelity, died on Tuesday at age 61... Read more
December 7, 2010
By GREGORY TWACHTMAN With members of the Patient-Centered Outcomes Research Institute’s Methodology Committee expected to be named by early in 2011,  one area where they could start to improve... Read more
December 1, 2010
FOR IMMEDIATE RELEASE KANSAS CITY, Mo. (December 1, 2010) – Five leaders in the medical innovation field released a white paper today titled The New Role of Academia in Drug Discovery and... Read more
November 30, 2010
By ANDREW POLLACK, For the last decade cancer drug developers have tried to  jam the accelerators that cause tumors to grow. Now they want to block the fuel line. Cancer cells, because of their... Read more
November 16, 2010
By ALICIA MUNDY Medicare officials are debating whether the agency should cover a new prostate-cancer treatment  that costs $93,000 per patient, sparking criticism from Dendreon Corp. investors and... Read more

Pages